登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C16H16ClN3O3S
化学文摘社编号:
分子量:
365.83
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
grade
pharmaceutical primary standard
API family
indapamide
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
CC1Cc2ccccc2N1NC(=O)c3ccc(Cl)c(c3)S(N)(=O)=O
InChI
1S/C16H16ClN3O3S/c1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)
InChI key
NDDAHWYSQHTHNT-UHFFFAOYSA-N
Gene Information
human ... SLC12A3(6559)
正在寻找类似产品? 访问 产品对比指南
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Indapamide USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Indapamide Tablets
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
signalword
Warning
hcodes
Hazard Classifications
Lact. - Repr. 2
存储类别
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
监管及禁止进口产品
此项目有
G Damien et al.
Clinical pharmacokinetics, 37 Suppl 1, 13-19 (1999-09-24)
In accordance with international guidelines recommending the use of low doses of antihypertensive agents, a new formulation of indapamide--indapamide sustained release (SR)--has been developed. Indapamide has been used worldwide for many years as an immediate release (IR) formulation at a
A J Matheson et al.
Drugs, 61(8), 1211-1229 (2001-07-24)
The fixed low-dose combination of the ACE inhibitor perindopril and the non-thiazide diuretic indapamide has been evaluated in the management of patients with mild to moderate hypertension. Combination therapy aims to improve overall therapeutic efficacy while minimising adverse effects. In
J Sassard et al.
Fundamental & clinical pharmacology, 19(6), 637-645 (2005-11-30)
The relationship between blood pressure (BP) and cardiovascular risk is clearly established; hypertension increases the rate of cardiovascular. High systolic blood pressure (SBP) may be the main parameter involved in cardiovascular morbidity and mortality. The benefit of lowering BP, particularly
John Chalmers et al.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 26(3), S21-S27 (2009-04-15)
The ADVANCE trial was designed to determine the effects of routine blood pressure lowering using a fixed combination of perindopril-indapamide on major vascular outcomes in patients with type 2 diabetes, regardless of initial blood pressure levels or the use of
Stéphane Laurent
Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 21(3), S11-S18 (2003-08-22)
To review the safety and efficacy of the very-low-dose combination of perindopril 2 mg and indapamide 0.625 mg (Per2/Ind0.625) in essential hypertension, in relation to blood pressure control and target-organ damage. We included in this review several double-blind, randomized studies
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 1338801-250MG | 04061838729699 |
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持